Cardiovascular Mortality in Type 2 Diabetes Patients with Incident Exposure to Insulin Glargine
Table 2
Competing risk analysis for stroke mortality.
Variables
Cumulative time
Cumulative dose
SHR (CI 95%)a
SHR (CI 95%)
Deaths ()
130
—
130
—
Age at inception
1.102 (1.079–1.125)
<0.001
1.102 (1.079–1.126)
<0.001
Male gender
1.168 (0.820–1.662)
0.390
1.163 (0.818–1.655)
0.400
TILb
1.118 (0.838–1.491)
0.450
1.140 (0.855–1.521)
0.372
Screening timec
0.892 (0.816–0.975)
0.012
0.897 (0.820–0.980)
0.016
Glargine
0.973 (0.927–1.020)
0.257
0.974 (0.929–1.021)
0.266
Basal human insulin
0.852 (0.747–0.973)
0.018
0.838 (0.727–0.967)
0.016
Regular insulin
0.994 (0.962–1.027)
0.724
0.996 (0.976–1.015)
0.668
Rapid-acting analogs
0.971 (0.875–1.076)
0.571
0.941 (0.868–1.020)
0.139
Premixed human insulin
0.990 (0.969–1.012)
0.372
1.002 (0.990–1.014)
0.729
Premixed analogue insulin
0.957 (0.931–0.984)
0.002
0.981 (0.957–1.006)
0.133
Metformin
0.958 (0.904–1.015)
0.149
0.999 (0.999–1.000)
0.344
Glimepiride
0.972 (0.889–1.062)
0.526
0.948 (0.546–1.649)
0.851
Gliclazide
0.854 (0.734–0.993)
0.040
0.947 (0.893–1.004)
0.068
Glipizide
0.895 (0.760–1.053)
0.181
0.875 (0.706–1.084)
0.221
Glibenclamide
0.907 (0.821–1.001)
0.053
0.818 (0.624–1.072)
0.145
Repaglinide
0.927 (0.836–1.028)
0.150
0.791 (0.494–1.265)
0.327
Pioglitazone
0.936 (0.789–1.110)
0.446
0.978 (0.889–1.076)
0.652
Rosiglitazone
0.866 (0.756–0.993)
0.039
0.557 (0.347–0.896)
0.652
SHR: subhazard ratios, similar to hazard ratios (HR) from the classic Cox regression. bTreatment intensity level (see Section 2). cTime between screening and date of insulin initiation (years).
